Revelation Health

Revelation Biosciences is a clinical-stage biopharmaceutical company focused on the development of immunotherapies and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate, REVTx-300, is being developed as a potential therapy for the prevention and treatment of acute kidney injury and chronic kidney disease. Their technology platform is centered on the use of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA), which acts as a selective Toll-like receptor 4 (TLR4) agonist to stimulate the innate immune system. Revelation Biosciences is also developing REVTx-100 for the prevention of healthcare-associated infections and REVTx-200 as an intranasal vaccine adjuvant.